Is Alphabet an Undervalued Growth Stock to Buy?
Alphabet (NASDAQ:GOOGL) is easily one of the most successful companies…
Sell
40
TRI.TO Quote, Financials, Valuation and Earnings
Last price:
$234.58
Seasonality move
:
3.73%
Day range:
$232.49 - $234.95
52-week range:
$188.00 - $243.42
Dividend yield:
1.26%
P/E ratio:
--
P/S ratio:
12.76x
P/B ratio:
6.55x
Volume:
152.2K
Avg. volume:
321.4K
1-year change:
23.64%
Market cap:
$110.5B
Revenue:
--
EPS (TTM):
--
Analysts' Opinion
-
Consensus RatingThomson Reuters has received a consensus rating of . The company's average rating is a based on 2 Buy ratings, 9 Hold ratings, and 1 Sell rating.
-
Price Target UpsideAccording to analysts' consensus price target of --, Thomson Reuters has an estimated upside of 4.19% from its current price of $234.53.
-
Price Target DownsideAccording to analysts, the lowest downside price target is -- representing 100% downside risk from its current price of $234.53.
Fair Value
-
According to the consensus of 0 analysts, Thomson Reuters has 4.19% upside to fair value with a price target of -- per share.
TRI.TO vs. S&P 500
-
Over the past 5 trading days, Thomson Reuters has underperformed the S&P 500 by -3.16% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Thomson Reuters does not have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Thomson Reuters has grown year-over-year revenues for 6 quarters straight. In the most recent quarter Thomson Reuters reported revenues of --.
Earnings Growth
-
Thomson Reuters earnings have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Thomson Reuters reported earnings per share of --.
Enterprise value:
114B
EV / Invested capital:
--
Price / LTM sales:
12.76x
EV / EBIT:
39.67x
EV / Revenue:
12.89x
PEG ratio (5yr expected):
--
EV / Free cash flow:
65.69x
Price / Operating cash flow:
65.05x
Enterprise value / EBITDA:
29.82x
Gross Profit (TTM):
--
Return On Assets:
--
Net Income Margin (TTM):
--
Return On Equity:
--
Return On Invested Capital:
--
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2021-03-31 | 2022-03-31 | 2023-03-31 | 2022-03-31 | 2023-03-31 | |
| Income Statement | ||||||
| Revenue | $8B | $8.1B | $8.8B | $2.1B | $2.4B | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | $2.7B | $1.6B | $2.5B | $524.2M | $687.3M | |
| EBITDA | $3.7B | $2.7B | $3.8B | $868.7M | $799.5M | |
| Diluted EPS | $15.28 | $4.18 | $3.26 | $2.61 | $2.15 | |
| Period Ending | 2019-03-31 | 2020-03-31 | 2021-03-31 | 2022-03-31 | 2023-03-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $5.3B | $4.2B | $5.2B | $2.9B | $4.6B | |
| Total Assets | $22B | $24B | $30B | $28.5B | $28.4B | |
| Current Liabilities | $2.9B | $4.5B | $4B | $2.9B | $5.1B | |
| Total Liabilities | $10B | $10.9B | $11.3B | $10.2B | $11.6B | |
| Total Equity | $12B | $13.1B | $18.7B | $18.3B | $16.9B | |
| Total Debt | $4.3B | $5.4B | $4.8B | $4.7B | $6B | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2021-03-31 | 2022-03-31 | 2023-03-31 | 2022-03-31 | 2023-03-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $2.6B | $2.1B | $2.5B | $348.2M | $361.2M | |
| Cash From Investing | $1.2B | -$1.9B | $1.9B | -$226.7M | $2.3B | |
| Cash From Financing | -$1.5B | -$2.6B | -$3B | -$278.6M | -$1.8B | |
| Free Cash Flow | $1.9B | $1.4B | $1.7B | $131.7M | $152.9M | |
TRI.TO
Sector
Market Cap
$110.5B
$764.1M
Price % of 52-Week High
96.35%
78.36%
Dividend Yield
1.26%
0%
Shareholder Yield
--
2.32%
1-Year Price Total Return
23.64%
-1.72%
Beta (5-Year)
0.411
0.899
Dividend yield:
1.26%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
1 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Sell
Level
$236.91
200-day SMA
Buy
Level
$226.25
Bollinger Bands (100)
Buy
Level
224.82 - 235.18
Chaikin Money Flow
Buy
Level
163.1M
20-day SMA
Sell
Level
$235.09
Relative Strength Index (RSI14)
Buy
Level
50.11
ADX Line
Buy
Level
28.19
Williams %R
Neutral
Level
-69.3989
50-day SMA
Buy
Level
$232.43
MACD (12, 26)
Buy
Level
1.34
25-day Aroon Oscillator
Buy
Level
60
On Balance Volume
Neutral
Level
56.3M
Financial Scores
--
Altman Z-Score
(Annual)
Level (--)
--
CA Score
(Annual)
Level (--)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (8)
--
Ohlson Score
Level (--)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
--
Fundamental Score
Level (--)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Thomson Reuters is the result of the $17.6 billion megamerger of Canada’s Thomson and the United Kingdom’s Reuters Group in 2008. In 2021, Thomson Reuters completed the sale of Refinitiv to LSE Group. Thomson Reuters' three largest segments are its legal professionals, Tax and accounting, and corporates segments. Legal professionals is about 42% of the firm's revenue and 47% of the firm's adjusted EBITDA. Tax and accounting makes up about 20%-25% of the firm's revenue and EBITDA. Corporates, which consists of legal professionals and tax and accounting products sold to corporations, also makes up about 20%-25% of the firm's revenue and EBITDA. Thomson Reuters' smaller segments include its Reuters news business and global print business.
Stock Forecast FAQ
In the current month, TRI.TO has received 2 Buy ratings 9 Hold ratings, and 1 Sell ratings. The TRI.TO average analyst price target in the past 3 months is --.
-
Where Will Thomson Reuters Stock Be In 1 Year?
According to analysts, the consensus estimate is that Thomson Reuters share price will rise to -- per share over the next 12 months.
-
What Do Analysts Say About Thomson Reuters?
Analysts are divided on their view about Thomson Reuters share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Thomson Reuters is a Sell and believe this share price will drop from its current level to --.
-
What Is Thomson Reuters's Price Target?
The price target for Thomson Reuters over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 2 of them rate the stock a Buy, 1 rates the stock a Sell, and 9 analysts rate the stock a Hold.
-
Is TRI.TO A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Thomson Reuters is a . 0 of 0 analysts rate the stock a at this time.
-
How Can I Buy Shares Of TRI.TO?
You can purchase shares of Thomson Reuters via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Thomson Reuters shares.
-
What Is The Thomson Reuters Share Price Today?
Thomson Reuters was last trading at $234.58 per share. This represents the most recent stock quote for Thomson Reuters. Yesterday, Thomson Reuters closed at $234.53 per share.
-
How To Buy Thomson Reuters Stock Online?
In order to purchase Thomson Reuters stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Tesla Going to Buy Uber?
Tesla has always been in the habit of making large,…
NVIDIA vs Broadcom Stock: Which Is Best?
If you want to invest in an AI-leading tech company,…
Stock Ideas
Buy
65
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 42x
Buy
57
Is NVDA Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 117x
Buy
53
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 37x
Alerts
Sell
40
MSTR alert for Dec 24
MicroStrategy [MSTR] is up 8.05% over the past day.
Sell
26
NUTX alert for Dec 24
Nutex Health [NUTX] is down 0.76% over the past day.
Sell
48
VRNA alert for Dec 24
Verona Pharma PLC [VRNA] is down 0.4% over the past day.
